Financing Correlated Drug Development Projects

2020 ◽  
Author(s):  
Andrew W. Lo ◽  
Kien Wei Siah
2020 ◽  
Author(s):  
Yosef Masoudi-Sobhanzadeh ◽  
Ali Masoudi-Nejad

Abstract Background: Drug repurposing aims to detect new benefits of the existing drugs and to reduce the time and cost of drug development projects. Although synthetic repurposing of drugs may be more useful than single repurposing in terms of reducing toxicity and enhancing efficacy, the researchers have not taken it into account. To address the issue, a novel datamining method is introduced and applied to the repositioning of drugs in hypertension (HT). This disease is a complex one and needs to efficient treatment plans to cure it better.Methods: A novel two-step data mining method, which is based on the If-Then association rules and a novel discrete optimization algorithm, is proposed and applied to the synthetic repurposing of drugs in HT. The required data are extracted from DruhBank, KEGG, and DrugR+ databases. Results: The outcomes presented that the proposed method outperforms other state-of-the-art approaches in terms of different statistical criteria. Since different methods failed to discover the list for some datasets, our method could suggest a combination of drugs for all the datasets. Conclusion: Due to using a minimum dosage of medicines, the synthetic method may revive some failed drug development projects and maybe a suitable plan for curing orphan and rare diseases. Also, to achieve better outcomes, it is essential to use efficient computational methods.


2020 ◽  
Author(s):  
Yosef Masoudi-Sobhanzadeh ◽  
Ali Masoudi-Nejad

Abstract Background Drug repurposing aims to detect the new benefits of the existing drugs and to reduce the spent time and cost of the drug development projects. Although synthetic repurposing of drugs may be more useful than single repurposing in terms of reducing toxicity and enhancing efficacy, the researchers have not taken it into account. To address the issue, a novel datamining method is introduced and applied to the repositioning of drugs in hypertension (HT), which is a serious medical condition and therefore needs to be dealt with effectively through making some improved treatment plans to help cure it. Results a novel two-step data mining method, which is based on the If-Then association rules and a novel discrete optimization algorithm, is proposed and applied to the synthetic repurposing of drugs in HT. The required data are extracted from DruhBank, KEGG, and DrugR+ databases. The outcomes presented that the proposed method outperforms the other state-of-the-art approaches in terms of different statistical criteria. In contrast to the previously proposed methods which failed to discover a list for some datasets, our method managed to suggest a combination of drugs for all the datasets. Conclusion The proposed synthetic method may revive some failed drug development projects and be a suitable plan for curing orphan and rare diseases due to using a low dosage of medicines. It is also essential to use some efficient computational methods to produce better results.


Author(s):  
Paul Grootendorst

Some brand drug companies have stymied attempts by generic drug companies to obtain samples of brand drugs needed to develop and gain regulatory approval for their generic products. This conduct, which has been reported in both the US and Canada, raises drug costs to drug plans and other payors and can lessen competition. The literature to date contains little empirical evidence on the prevalence of this conduct, the attendant effects on generic drug market launches and costs incurred by drug payors. This paper addresses these questions for Canada, using data on the drug development projects undertaken by the members of the Canadian Generic Pharmaceutical Association over the period 2015–2019. I found that about 16% of generic drug development projects were delayed due to originator firm efforts to impede access to samples of their drugs. The median generic drug launch delay (among affected drugs) attributable to the challenged conduct was 6 months. The additional costs to drug payors from the resulting delays in generic drug launches over the analysis period was in the order of $284 million, or $57 million annually. This study did not explore the additional generic drug development costs attributable to the challenged conduct.


Sign in / Sign up

Export Citation Format

Share Document